MAP2K7 and lung carcinoma: We suggested the effects of PD-L1 Ab or MEK/Erk inhibition on directly enhancing the NK cell cytotoxicity to cisplatin-resistant lung cancer cells, but Benson et al. 10 suggested that the PD-L1Ab effect may be through affecting NK cell trafficking and immune complex formation with tumor cells.